Guggenheim analyst Eddie Hickman raised the firm’s price target on GH Research (GHRS) to $34 from $29 and keeps a Buy rating on the shares after the company reported FY25 results and reiterated continued clinical and regulatory progress across the GH001 program. The firm, which says it continues to believe GH001 has generated “some of the most robust short-term efficacy” in the treatment-resistant depression space, remains confident in the regulatory path.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GHRS:
- GH Research: Advancing Phase 3 TRD Program Post‑Hold with Strong Cash Runway Supports Buy Rating
- GH Research price target raised to $42 from $39 at Citizens
- GH Research: Phase 3 Readiness, Expanding Indications, and Valuation Upside Reinforce Buy Rating
- Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
- GH Research Posts 2025 Results as TRD Drug GH001 Clears Key Phase 2b Milestone